NOVO-NORDISK A/S-SPONS ADR (NVO) Stock News
NYSE:NVO - New York Stock Exchange, Inc. - US6701002056 - ADR - Currency: USD
NVO Latest News, Press Relases and Analysis
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Technical Breakout Potential
NOVO-NORDISK (NYSE:NVO) is a strong growth stock with solid fundamentals and a promising technical setup, offering potential for a breakout.
Investors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR could be undervalued. NYSE:NVO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
3 Red-Hot Growth Stocks to Buy in 2025
Spotify offers a music streaming service and is seeing healthy traction in paid membership, rising profitability and free cash flows. Lyft just turned profitable and free-cash-flow-positive, and has a huge total addressable market that will allow for many more years of growth. It pays to spot promising growth stocks that you can buy and keep for years or even decades.
Autodesk price target raised to $345 from $340 at Rosenblatt
Rosenblatt analyst Blair Abernethy raised the firm’s price target on Autodesk (ADSK) to $345 from $340 and keeps a Buy rating on the shares after the company reported Q1 results marginally ahead of the firm’s forecast. For its updated outlook, the positive impact of forex on Autodesk’s billings growth is now being partially offset by added caution to better reflect macro uncertainty, notes the analyst, who is making “minor adjustments” to the firm’s forecasts post Q1. Published first on TheFly –
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high […]
Was Jim Cramer Right About Pfizer Inc. (PFE)?
We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 17, a caller asked about Pfizer Inc. (NYSE:PFE), which had struggled post-COVID. Cramer […]
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy.
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now
Alphabet's stock has reached dirt-cheap levels. Investors need to look past the price they could have bought them for just a month ago, as those prices are long gone. Furthermore, investors shouldn't sit on the sidelines waiting for another drop, as it may not come for some time.
The Charles Schwab Corporation (NYSE:SCHW): Jim Cramer Shares His Latest Thoughts
We recently published a list of Jim Cramer Shares Thoughts On Big Tech As Part Of These 12 Stocks. In this article, we are going to take a look at where The Charles Schwab Corporation (NYSE:SCHW) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, […]
Novo Nordisk's former chief makes comeback to steer choice of new CEO
COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet." His appointment as an observer on the board follows the removal on Friday of current CEO Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation - the company's controlling shareholder, which Sorensen chairs. Jorgensen succeeded Sorensen as CEO in 2017.
Mentions: LLY
Cigna Offers New Weight-Loss Drug Pricing Plan to Boost Use
Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will make the medicines available to more patients.
Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal
Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company’s recently disclosed $6 billion licensing deal with 3SBio Inc. to develop and market the cancer treatment SSGJ-707. While a notable venture at face value, the deal has raised questions about Pfizer’s continued collaboration with […]
5 Single-Stock ETFs That Doubled in a Month
We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Big Money Keeps Buying Palantir
Big Money inflows push shares of data mining company Palantir Technologies, Inc. (PLTR) higher.
Profits, Big Money Inflows Send SEI Shares Higher
SEI Investments Company (SEIC) sees Big Money inflows after strong earnings.
Leadership Transition at Schrödinger: Richie Jain Named CFO
On May 20, Schrödinger, Inc. (NASDAQ:SDGR) announced the departure of Chief Financial Officer Geoffrey Porges, MBBS., who is stepping down to pursue other opportunities. Richie Jain, previously Senior Vice President of Strategic Finance and Head of Corporate and Business Development, will succeed him. Dr. Porges will continue as an advisor until June 6, 2025, to […]
BMO Capital Maintains Cautious Outlook on Novo Nordisk Amid CEO Transition
On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change as a response to competitive pressures and shareholder demands, but warn that without a strategic shift, challenges may persist. On May 16, Novo […]
F5 and Red Hat Expand AI Collaboration for Secure, Scalable Applications
On May 19, F5, Inc. (NASDAQ:FFIV) announced an enhanced partnership with Red Hat, the leading provider of open-source solutions, aimed at helping enterprises securely deploy and scale high-performance AI applications. The collaboration enables businesses to accelerate retrieval-augmented generation (RAG), model serving, and scalable data ingestion, fostering AI adoption without compromising security. AI deployment is surging, […]
Home Depot Earnings Preview: Evercore Sees Rebound Potential
Ahead of the company’s May 20 first-quarter earnings release, a team of Evercore ISI analysts, led by Greg Melich, added Home Depot Inc.(NYSE:HD) to their Tactical Outperform list on May 19. The analyst firm anticipates that Home Depot Inc.(NYSE:HD) will restate its 2025 guidance for a 2% decline in earnings per share, or approximately $14.95, which aligns with […]
Jim Cramer on Home Depot (HD): “I Like It Long Term”
We recently published a list of 15 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Home Depot, Inc. (NYSE:HD) stands against other stocks on Jim Cramer’s radar On Friday’s episode of Mad Money, Jim Cramer reflected on this week’s market performance, with attention to upcoming earnings […]
Novo Nordisk Places Bet on CEO Shake-Up to Reclaim Edge in Weight Loss Drug Race
As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO) abruptly announced the resignation of veteran CEO Lars Fruergaard Jørgensenm last week. The stock has dropped by over 49% in the past year, wiping out over […]
Mentions: LLY
Why Novo Nordisk Stock Popped on Tuesday
If you can't beat Novo Nordisk, maybe you should join 'em?
What Makes Novo Nordisk (NVO) a Lucrative Investment?
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index declined by -4.3% in Q1 2025 due to a tariff war and a shift away from AI-related tech stocks. Amid the tech-led sell-off, the […]
UBS Upgrades Archer Daniels (ADM) Stock to Buy, Lifts PT
On May 19, UBS analyst Manav Gupta upped Archer-Daniels-Midland Company (NYSE:ADM)’s stock from “Neutral” to “Buy,” raising the price objective to $60 from the prior target of $55. The analyst highlighted the potential policy benefits, together with an optimistic outlook for its nutrition segment, as critical drivers. The House’s budget reconciliation bill has made it […]
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie
Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.